Skip to Content
Cancer Diagnosis Program (CDP) — Biorepositories & Biospecimen Research Branch (BBRB) Cancer Diagnosis Program (CDP) Biorepositories & Biospecimen Research Branch (BBRB)
Contact NExT
Show menu
Search this site
Last Updated: 10/24/18

Current Funding Opportunities

Visit this page often to find new biospecimen-related funding opportunities from the NCI Biorepositories and Biospecimen Research Branch and other NIH Research Programs.

Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trials Not Allowed)

PAR-18-947

Posted date: September 28, 2018
Open date (Earliest submission date): October 28, 2018
Application receipt dates: November 28, 2018; March 14, 2019; July 11, 2019; November 7, 2019; March 11, 2020; July 9, 2020; November 9, 2020; March 15, 2021; July 11, 2021

This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies and blood biospecimens utilized as “liquid biopsies.” Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), pleural aspirates, and blood utilized for liquid biopsies. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.

https://grants.nih.gov/grants/guide/pa-files/PAR-18-947.html

CDP contact: Dr. Abhi Rao, 240-276-5715, abhi.rao@nih.gov

Cancer Moonshot Biobank Project - Institutional Review Board (IRB)

In support of the Cancer Moonshot Biobank, Leidos Biomedical Research, Inc., seeks a subcontractor to carry out the IRB review requirements as specified under the Health and Human Services (HHS) regulations at 45 Code of Federal Regulations (CFR) part 46. There are two main tasks required for this project: 1) to serve as a single IRB for up to 150 participating Biospecimen Source Sites (BSS), and 2) to serve as the IRB for the Biospecimen Core Resource (BCR). Proposal Due Date: Wednesday, September 5, 2018.

https://frederick.cancer.gov/workwithus/solicitations/s18-095

Past Funding Opportunities

A complete list of past funding opportunities is available in the Past Funding Opportunities section.

Complementary Funding Opportunities

A list of complementary funding opportunities is available in the Complementary Funding Opportunities section.